Francis Medical received the FDA Breakthrough Device Designation for Vanquish Minimally Invasive Prostate Cancer Therapy

CAR-T Digest - August 2020

01 Aug 2023: Vanquish Minimally Invasive Prostate Cancer Therapy: Breakthrough Device Designation by the FDA

Vanquish water vapor technology applies the thermal energy stored in a few drops of sterile water to deliver targeted treatments to the cancerous tissue through a simple transurethral procedure
The therapy is designed to ablate cancer cells while protecting surrounding structures, lessening the likelihood of life-altering side effects common with other prostate cancer treatments
Company is planning to initiate VAPOR 2 trial in support of an FDA submission for the US market clearance
“We are excited that the FDA has recognized the potential of our technology to be a breakthrough for patients who today face the difficult choice between addressing their cancer and avoiding the debilitating morbidities often associated with current standards of care.” said Michael Kujak, Francis Medical president, and chief executive officer